Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2013, Article ID 654218, 8 pages
http://dx.doi.org/10.1155/2013/654218
Clinical Study

Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study

1Nagoya Rheumatology Clinic/Initiative for Rheumatology and Osteoporosis, Nagoya 4500002, Japan
2Lilly Research Laboratories Japan, Eli Lilly Japan K.K., 7-1-5 Isogami dori, Chuoku, Kobe 6510086, Japan
3Statistical Programming, PharmaNet/i3 LLC, Indianapolis, IN 46280, USA
4Statistics, Eli Lilly and Company, Indianapolis, IN 46285, USA
5Surveillance & Epidemiology, Global Patient Safety Japan, Eli Lilly Japan K.K., Kobe 6510086, Japan
6Global Health Outcomes, Eli Lilly Australia Pty Ltd, Sydney 2114, Australia
7Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46285, USA

Received 5 August 2013; Accepted 25 October 2013

Academic Editor: Saeko Fujiwara

Copyright © 2013 Ikuko Tanaka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Yoshimura, S. Muraki, H. Oka et al., “Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study,” Journal of Bone and Mineral Metabolism, vol. 27, no. 5, pp. 620–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Hagino, K. Furukawa, S. Fujiwara et al., “Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan,” Osteoporosis International, vol. 20, no. 4, pp. 543–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Orimo, Y. Yaegashi, T. Onoda, Y. Fukushima, T. Hosoi, and K. Sakata, “Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends,” Archives of Osteoporosis, vol. 4, no. 1-2, pp. 71–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Suzuki and H. Yoshida, “Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women,” Osteoporosis International, vol. 21, no. 1, pp. 71–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Shiraki, T. Kuroda, and S. Tanaka, “Established osteoporosis associated with high mortality after adjustment for age and co-mobidities in postmenopausal Japanese women,” Internal Medicine, vol. 50, no. 5, pp. 397–404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Miyakoshi, E. Itoi, M. Kobayashi, and H. Kodama, “Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis,” Osteoporosis International, vol. 14, no. 12, pp. 1007–1012, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Miyakoshi, M. Hongo, S. Maekawa, Y. Ishikawa, Y. Shimada, and E. Itoi, “Back extensor strength and lumbar spinal mobility are predictors of quality of life in patients with postmenopausal osteoporosis,” Osteoporosis International, vol. 18, no. 10, pp. 1397–1403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Fujiwara, E. Hamaya, W. Goto et al., “Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan,” Bone, vol. 49, no. 3, pp. 520–525, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Oinuma, M. Sakuma, and N. Endo, “Secular change of the incidence of four fracture types associated with senile osteoporosis in Sado, Japan: the results of a 3-year survey,” Journal of Bone and Mineral Metabolism, vol. 28, no. 1, pp. 55–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. P. Krueger, B. A. Berger, and B. Felkey, “Medication adherence and persistence: a comprehensive review,” Advances in Therapy, vol. 22, no. 4, pp. 313–356, 2005. View at Google Scholar · View at Scopus
  11. J. A. Cramer, A. Roy, A. Burrell et al., “Medication compliance and persistence: terminology and definitions,” Value in Health, vol. 11, no. 1, pp. 44–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Lekkerkerker, J. A. Kanis, N. Alsayed et al., “Adherence to treatment of osteoporosis: a need for study,” Osteoporosis International, vol. 18, no. 10, pp. 1311–1317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. T. W. Downey, S. H. Foltz, S. J. Boccuzzi, M. A. Omar, and K. H. Kahler, “Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting,” Southern Medical Journal, vol. 99, no. 6, pp. 570–575, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. T. Gold, I. M. Alexander, and M. P. Ettinger, “How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy,” Annals of Pharmacotherapy, vol. 40, no. 6, pp. 1143–1150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. J. Caro, K. J. Ishak, K. F. Huybrechts, G. Raggio, and C. Naujoks, “The impact of compliance with osteoporosis therapy on fracture rates in actual practice,” Osteoporosis International, vol. 15, no. 12, pp. 1003–1008, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. E. S. Siris, S. T. Harris, C. J. Rosen et al., “Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases,” Mayo Clinic Proceedings, vol. 81, no. 8, pp. 1013–1022, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. F.-E. Cotté, F. Mercier, and G. de Pouvourville, “Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis,” Clinical Therapeutics, vol. 30, no. 12, pp. 2410–2422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yu, R. T. Burge, S. A. Foster, S. Gelwicks, and E. S. Meadows, “The impact of teriparatide adherence and persistence on fracture outcomes,” Osteoporosis International, vol. 23, no. 3, pp. 1103–1113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Hiligsmann, A. Boonen, V. Rabenda, and J.-Y. Reginster, “The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 12, no. 2, pp. 159–166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-Y. Reginster, “Adherence and persistence: impact on outcomes and health care resources,” Bone, vol. 38, no. 2, supplement 2, pp. S18–S21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. D. H. Solomon, J. Avorn, J. N. Katz et al., “Compliance with osteoporosis medications,” Archives of Internal Medicine, vol. 165, no. 20, pp. 2414–2419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Blouin, A. Dragomir, L.-G. Ste-Marie, J. C. Fernandes, and S. Perreault, “Discontinuation of antiresorptive therapies: a comparison between 1998–2001 and 2002–2004 among osteoporotic women,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 3, pp. 887–894, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Silverman and D. T. Gold, “Compliance and persistence with osteoporosis medications: a critical review of the literature,” Reviews in Endocrine & Metabolic Disorders, vol. 11, no. 4, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Seeman, J. Compston, J. Adachi et al., “Non-compliance: the Achilles' heel of anti-fracture efficacy,” Osteoporosis International, vol. 18, no. 6, pp. 711–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Kothawala, E. Badamgarav, S. Ryu, R. M. Miller, and R. J. Halbert, “Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis,” Mayo Clinic Proceedings, vol. 82, no. 12, pp. 1493–1501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Kamatari, S. Koto, N. Ozawa et al., “Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate,” Journal of Bone and Mineral Metabolism, vol. 25, no. 5, pp. 302–309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Gorai, Y. Tanaka, S. Hattori, and Y. Iwaoki, “Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women,” Journal of Bone and Mineral Metabolism, vol. 28, no. 2, pp. 176–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Osaki, K. Tatsuki, T. Hashikawa et al., “Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women,” Osteoporosis International, vol. 23, no. 2, pp. 695–703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. “Forteo [package insert],” Eli Lilly Japan K.K., Kobe, Japan, 2011.
  30. R. M. Neer, C. D. Arnaud, J. R. Zanchetta et al., “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 344, no. 19, pp. 1434–1441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. B. L. Langdahl, G. Rajzbaum, F. Jakob et al., “Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS),” Calcified Tissue International, vol. 85, no. 6, pp. 484–493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. N. K. Arden, S. Earl, D. J. Fisher, C. Cooper, S. Carruthers, and M. Goater, “Persistence with teriparatide in patients with osteoporosis: the UK experience,” Osteoporosis International, vol. 17, no. 11, pp. 1626–1629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Briot, P. Ravaud, P. Dargent-Molina, M. Zylberman, S. Liu-Leage, and C. Roux, “Persistence with teriparatide in postmenopausal osteoporosis; Impact of a patient education and follow-up program: the French experience,” Osteoporosis International, vol. 20, no. 4, pp. 625–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Foster, K. A. Foley, E. S. Meadows et al., “Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance,” Osteoporosis International, vol. 22, no. 2, pp. 551–557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Ziller, S. P. Zimmermann, M. Kalder et al., “Adherence and persistence in patients with severe osteoporosis treated with teriparatide,” Current Medical Research and Opinion, vol. 26, no. 3, pp. 675–681, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Mulgund, K. A. Beattie, A. K. Wong, A. Papaioannou, and J. D. Adachi, “Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture,” Therapeutic Advances in Musculoskeletal Disease, vol. 1, no. 1, pp. 5–11, 2009. View at Publisher · View at Google Scholar
  37. R. S. Weinstein, “Glucocorticoid-induced osteoporosis and osteonecrosis,” Endocrinology and Metabolism Clinics of North America, vol. 41, no. 3, pp. 595–611, 2012. View at Publisher · View at Google Scholar
  38. J. D. Adachi, D. A. Hanley, J. K. Lorraine, and M. Yu, “Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study,” Clinical Therapeutics, vol. 29, no. 9, pp. 2055–2067, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. A. Cramer, M. M. Amonkar, A. Hebborn, and R. Altman, “Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis,” Current Medical Research and Opinion, vol. 21, no. 9, pp. 1453–1460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Weycker, D. Macarios, J. Edelsberg, and G. Oster, “Compliance with drug therapy for postmenopausal osteoporosis,” Osteoporosis International, vol. 17, no. 11, pp. 1645–1652, 2006. View at Publisher · View at Google Scholar · View at Scopus